O	0	10	Prolonging
O	11	14	the
O	15	23	duration
O	24	26	of
B-intervention	27	31	post
I-intervention	31	32	-
I-intervention	32	40	infusion
I-intervention	41	46	scalp
I-intervention	47	54	cooling
O	55	57	in
O	58	61	the
O	62	72	prevention
O	73	75	of
B-condition	76	89	anthracycline
I-condition	89	90	-
I-condition	90	97	induced
I-condition	98	106	alopecia
O	106	107	:
O	108	109	a
O	110	120	randomised
O	121	126	trial
O	127	129	in
O	130	138	patients
O	139	143	with
O	144	150	breast
O	151	157	cancer
O	158	165	treated
O	166	170	with
O	171	179	adjuvant
O	180	192	chemotherapy
O	192	193	.

O	194	199	Scalp
O	200	207	cooling
O	208	210	as
O	211	212	a
O	213	219	method
O	220	222	to
O	223	229	reduce
O	230	233	the
O	234	243	incidence
O	244	246	of
O	247	259	chemotherapy
O	259	260	-
O	260	267	induced
O	268	276	alopecia
O	277	278	(
O	278	281	CIA
O	281	282	)
O	283	285	is
O	286	298	increasingly
O	299	303	used
O	304	306	in
O	307	312	daily
O	313	321	practice
O	322	331	worldwide
O	331	332	.

O	333	340	However
O	340	341	,
O	342	344	in
O	345	353	patients
O	354	361	treated
O	362	366	with
O	367	368	5
O	368	369	-
O	369	381	fluorouracil
O	381	382	,
O	383	393	epirubicin
O	394	397	and
O	398	414	cyclophosphamide
O	415	416	(
O	416	419	FEC
O	419	420	)
O	420	421	,
O	422	427	scalp
O	428	435	cooling
O	436	441	fails
O	442	444	in
O	445	447	48
O	447	448	-
O	448	450	67
O	450	451	%
O	452	454	of
O	455	463	patients
O	463	464	.

O	465	469	This
O	470	475	study
O	476	488	investigated
O	489	492	the
O	493	501	efficacy
O	502	504	of
O	505	513	extended
O	514	522	duration
O	523	525	of
O	526	530	post
O	530	531	-
O	531	539	infusion
O	540	545	scalp
O	546	553	cooling
O	554	556	in
O	557	563	breast
O	564	570	cancer
O	571	579	patients
O	580	587	treated
O	588	592	with
O	593	597	this
O	598	605	regimen
O	605	606	.

O	607	609	In
O	610	614	this
O	615	626	prospective
O	627	632	multi
O	632	633	-
O	633	639	centre
O	640	650	randomised
O	651	656	study
O	656	657	,
B-total-participants	658	661	102
B-eligibility	662	670	patients
I-eligibility	671	675	with
I-eligibility	676	681	early
I-eligibility	682	688	breast
I-eligibility	689	695	cancer
I-eligibility	696	703	treated
I-eligibility	704	708	with
I-eligibility	709	717	adjuvant
I-eligibility	718	721	FEC
I-eligibility	722	734	chemotherapy
O	735	739	were
O	740	748	randomly
O	749	757	assigned
O	758	760	in
O	761	762	a
O	763	764	1
O	764	765	:
O	765	766	1
O	767	772	ratio
O	773	775	to
O	776	777	a
B-control	778	782	post
I-control	782	783	-
I-control	783	791	infusion
I-control	792	799	cooling
I-control	800	804	time
I-control	805	807	of
I-control	808	810	90
O	811	813	or
O	814	817	150
O	818	821	min
O	821	822	.

O	823	826	The
O	827	834	primary
O	835	843	endpoint
O	844	847	was
O	848	851	the
B-outcome-Measure	852	856	need
I-outcome-Measure	857	859	to
I-outcome-Measure	860	864	wear
I-outcome-Measure	865	866	a
I-outcome-Measure	867	870	wig
I-outcome-Measure	871	873	or
I-outcome-Measure	874	879	other
I-outcome-Measure	880	884	head
I-outcome-Measure	885	893	covering
I-outcome-Measure	894	896	to
I-outcome-Measure	897	901	mask
I-outcome-Measure	902	909	visible
I-outcome-Measure	910	914	hair
I-outcome-Measure	915	919	loss
O	919	920	.

B-cv-bin-abs	921	928	Sixteen
O	929	932	out
O	933	935	of
B-control-participants	936	938	48
O	939	947	patients
O	948	949	(
B-cv-bin-percent	949	951	33
I-cv-bin-percent	951	952	%
O	952	953	)
O	954	961	treated
O	962	966	with
O	967	969	90
O	970	973	min
O	974	976	of
O	977	981	post
O	981	982	-
O	982	990	infusion
O	991	998	cooling
B-outcome	999	1002	did
I-outcome	1003	1006	not
I-outcome	1007	1011	need
I-outcome	1012	1015	any
I-outcome	1016	1020	head
I-outcome	1021	1029	covering
O	1029	1030	,
O	1031	1039	compared
O	1040	1044	with
B-iv-bin-abs	1045	1047	21
O	1048	1051	out
O	1052	1054	of
B-intervention-participants	1055	1057	46
O	1058	1066	patients
O	1067	1068	(
B-iv-bin-percent	1068	1070	45
I-iv-bin-percent	1070	1071	%
O	1071	1072	)
O	1073	1080	treated
O	1081	1085	with
O	1086	1089	150
O	1090	1093	min
O	1094	1096	of
O	1097	1101	post
O	1101	1102	-
O	1102	1110	infusion
O	1111	1118	cooling
O	1119	1120	(
O	1120	1121	p
O	1122	1123	=
O	1124	1125	0
O	1125	1126	.
O	1126	1127	2
O	1127	1128	)
O	1128	1129	.

B-outcome	1130	1133	WHO
I-outcome	1134	1140	grades
I-outcome	1141	1142	2
I-outcome	1142	1143	-
I-outcome	1143	1144	3
I-outcome	1145	1146	(
I-outcome	1146	1154	moderate
I-outcome	1154	1155	-
I-outcome	1155	1163	complete
I-outcome	1163	1164	)
I-outcome	1165	1173	alopecia
O	1174	1178	were
O	1179	1187	reported
O	1188	1192	more
O	1193	1198	often
O	1199	1201	in
O	1202	1210	patients
O	1211	1218	treated
O	1219	1223	with
O	1224	1226	90
O	1226	1227	-
O	1227	1230	min
O	1231	1235	post
O	1235	1236	-
O	1236	1244	infusion
O	1245	1252	cooling
O	1253	1257	time
O	1258	1259	(
O	1259	1260	n
O	1261	1262	=
B-cv-bin-abs	1263	1265	25
O	1265	1266	/
B-control-participants	1266	1268	51
O	1269	1270	(
B-cv-bin-percent	1270	1272	49
I-cv-bin-percent	1272	1273	%
O	1273	1274	)
O	1275	1281	versus
O	1282	1283	n
O	1284	1285	=
B-iv-bin-abs	1286	1288	17
O	1288	1289	/
B-intervention-participants	1289	1291	51
O	1292	1293	(
B-iv-bin-percent	1293	1295	33
I-iv-bin-percent	1295	1296	%
O	1296	1297	)
O	1297	1298	;
O	1299	1300	p
O	1301	1302	=
O	1303	1304	0
O	1304	1305	,
O	1305	1307	02
O	1307	1308	)
O	1308	1309	.

O	1310	1315	Scalp
O	1316	1323	cooling
O	1324	1327	was
O	1328	1332	well
O	1332	1333	-
O	1333	1342	tolerated
O	1343	1344	(
O	1344	1348	mean
O	1349	1355	Visual
O	1356	1364	Analogue
O	1365	1370	Score
O	1371	1372	7
O	1372	1373	.
O	1373	1374	4
O	1374	1375	)
O	1376	1379	and
O	1380	1384	only
O	1385	1390	three
O	1391	1399	patients
O	1400	1401	(
O	1401	1402	3
O	1402	1403	%
O	1403	1404	)
B-outcome	1405	1412	stopped
I-outcome	1413	1416	due
I-outcome	1417	1419	to
I-outcome	1420	1431	intolerance
O	1432	1438	during
O	1439	1448	treatment
O	1448	1449	.

O	1450	1459	Extending
O	1460	1463	the
O	1464	1472	duration
O	1473	1475	of
O	1476	1478	90
O	1478	1479	-
O	1479	1482	min
O	1483	1487	post
O	1487	1488	-
O	1488	1496	infusion
O	1497	1502	scalp
O	1503	1510	cooling
O	1511	1513	to
O	1514	1517	150
O	1518	1521	min
O	1522	1524	in
O	1525	1533	patients
O	1534	1541	treated
O	1542	1546	with
O	1547	1555	adjuvant
O	1556	1559	FEC
O	1560	1572	chemotherapy
O	1573	1576	was
O	1577	1581	well
O	1581	1582	-
O	1582	1591	tolerated
O	1592	1595	but
O	1596	1599	did
O	1600	1603	not
O	1604	1617	significantly
O	1618	1626	diminish
O	1627	1630	the
O	1631	1635	need
O	1636	1639	for
O	1640	1644	head
O	1645	1653	covering
O	1653	1654	.

O	1655	1662	However
O	1662	1663	,
O	1664	1670	grades
O	1671	1672	2
O	1672	1673	-
O	1673	1674	3
O	1675	1683	alopecia
O	1684	1687	was
O	1688	1692	seen
O	1693	1697	less
O	1698	1703	often
O	1704	1708	with
O	1709	1718	prolonged
O	1719	1723	post
O	1723	1724	-
O	1724	1732	infusion
O	1733	1738	scalp
O	1739	1746	cooling
O	1746	1747	.
